WPD Pharmaceuticals Inc. (WPDPF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 229.29 Thousand USD | 0.0% |
| 2022 | - USD | -100.0% |
| 2021 | 825.46 Thousand USD | 811.45% |
| 2020 | 90.56 Thousand USD | -64.42% |
| 2019 | 254.51 Thousand CAD | 1994.05% |
| 2018 | 12.15 Thousand USD | -71.84% |
| 2017 | 43.16 Thousand USD | -43.96% |
| 2016 | 77.01 Thousand USD | 341.34% |
| 2015 | 17.45 Thousand USD | 1.44% |
| 2014 | 17.2 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 237.68 Thousand USD | 5.95% |
| 2024 Q2 | 249 Thousand USD | 5.84% |
| 2023 Q4 | 229.29 Thousand USD | 9.97% |
| 2023 Q3 | 208.5 Thousand USD | 4.65% |
| 2023 Q2 | 199.23 Thousand USD | 1247.37% |
| 2023 Q1 | 14.78 Thousand USD | 0.0% |
| 2023 FY | 229.29 Thousand USD | 0.0% |
| 2022 Q4 | - CAD | 0.0% |
| 2022 FY | - USD | -100.0% |
| 2021 Q1 | 91.07 Thousand USD | 0.56% |
| 2021 FY | 825.46 Thousand USD | 811.45% |
| 2021 Q3 | 241.33 Thousand USD | 210.9% |
| 2021 Q2 | 77.62 Thousand USD | -14.77% |
| 2021 Q4 | 825.46 Thousand USD | 242.04% |
| 2020 Q3 | 11.56 Thousand USD | -45.3% |
| 2020 FY | 90.56 Thousand USD | -64.42% |
| 2020 Q4 | 90.56 Thousand USD | 682.97% |
| 2020 Q2 | 21.14 Thousand USD | 0.0% |
| 2019 FY | 254.51 Thousand CAD | 1994.05% |
| 2018 FY | 12.15 Thousand USD | -71.84% |
| 2017 FY | 43.16 Thousand USD | -43.96% |
| 2016 FY | 77.01 Thousand USD | 341.34% |
| 2015 FY | 17.45 Thousand USD | 1.44% |
| 2014 FY | 17.2 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Qrons Inc. | 351.84 Thousand USD | 34.832% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.23% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -87.176% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -791.524% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.872% |
| BioStem Technologies, Inc. | 4.71 Million USD | 95.133% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 96.095% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.471% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.497% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 69.679% |
| Skye Bioscience, Inc. | 4.61 Million USD | 95.032% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | 310 Thousand USD | 26.035% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 63.609% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.444% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 94.437% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 42.941% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.165% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 90.142% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 75.82% |
| Mesoblast Limited | 118.7 Million USD | 99.807% |
| Marizyme, Inc. | 18.71 Million USD | 98.775% |
| Genus plc | 233.1 Million USD | 99.902% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 92.175% |
| Pharming Group N.V. | 171.54 Million USD | 99.866% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 74.181% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 82.934% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 69.428% |
| ContraFect Corporation | 2.88 Million USD | 92.041% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -69.235% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 84.147% |
| IMV Inc. | 28.88 Million USD | 99.206% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 95.948% |
| MultiCell Technologies, Inc. | 202.58 USD | -113085.408% |
| ONE Bio Corp. | 19.71 Million USD | 98.837% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.601% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | 84.66% |
| Q BioMed Inc. | 4.1 Million USD | 94.421% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.307% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 81.334% |
| Biomind Labs Inc. | 735.54 Thousand USD | 68.827% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.661% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 92.423% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.236% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 36.257% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -62.022% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 89.847% |
| GB Sciences, Inc. | 1.75 Million USD | 86.967% |
| Alpha Cognition Inc. | 1.22 Million USD | 81.211% |
| HST Global, Inc. | 98.31 Thousand USD | -133.211% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 7.812% |
| Halberd Corporation | 150 Thousand USD | -52.861% |
| Enzolytics Inc. | 996.33 Thousand USD | 76.987% |
| Agentix Corp. | 50 Thousand USD | -358.582% |
| Resverlogix Corp. | 6.49 Million USD | 96.468% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 10.29% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 98.854% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 96.758% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 91.535% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -2142.455% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.945% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -14.293% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 90.437% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -54.245% |
| Kadimastem Ltd | 891.22 Thousand USD | 74.272% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 8.35% |
| LadRx Corporation | 33.6 Thousand USD | -582.292% |
| Cell Source, Inc. | 9.25 Million USD | 97.522% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 69.679% |
| NovAccess Global Inc. | 2.19 Million USD | 89.577% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -0.4% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -8.682% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 95.399% |
| Mobile Lads Corp. | 484.28 Thousand USD | 52.654% |
| CytoDyn Inc. | 30.07 Million USD | 99.238% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 97.068% |
| SYBLEU INC | 477.5 Thousand USD | 51.981% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 95.158% |
| International Stem Cell Corporation | 4.17 Million USD | 94.512% |
| Bioxytran, Inc. | 1.92 Million USD | 88.089% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -267.377% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 89.486% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 97.243% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 97.329% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 85.259% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 14.444% |
| Neutra Corp. | 54.15 Thousand USD | -323.39% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 87.47% |
| PureTech Health plc | 25.51 Million USD | 99.101% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 81.271% |
| IXICO plc | 472.02 Thousand USD | 51.424% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.521% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.632% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Cellectis S.A. | 92.77 Million USD | 99.753% |